About Us

MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. iNKTs have a dual-mechanism of action with an internal targeting and homing device (iTCR) that modulates both arms of immunity, innate and adaptive. iNKTs combine the killing features of natural killer (NK) cells with the durable memory response of T cells. iNKT cells have been demonstrated to be highly effective in treating solid tumor cancers in their native form and MiNK has demonstrated that these cells can be further engineered or edited for super-targeting.

Executive Leadership

X

Scientific Advisory Board

Board of Directors

Management

Manuel Hidalgo, M.D., Ph.D.

Scientific Advisor

Manuel Hidalgo, M.D., Ph.D.
Scientific Advisor

Mark Exley, Ph.D.

Scientific Advisor

Mark Exley, Ph.D.
Scientific Advisor

Jenny Gumperz, Ph.D.

Scientific Advisor

Jenny Gumperz, Ph.D.
Scientific Advisor

Lydia Lynch, Ph.D.

Scientific Advisor

Lydia Lynch, Ph.D.
Scientific Advisor

Marcela Maus, M.D., Ph.D.

Scientific Advisor

Marcela Maus, M.D., Ph.D.
Scientific Advisor

Hagop Youssoufian, M.D.

Scientific Advisor

Hagop Youssoufian, M.D.
Scientific Advisor

Jennifer Buell, Ph.D.

Chairman and CEO

Jennifer Buell, Ph.D.
Chairman and CEO

Garo Armen, Ph.D.

Executive Chairman

Garo Armen, Ph.D.
Executive Chairman

Brian Corvese

Director

Brian Corvese
Director

Peter Behner, Ph.D.

Director

Peter Behner, Ph.D.
Director

Barbara Ryan

Director

Barbara Ryan
Director

Walter Flamenbaum, M.D.

Vice-chairman

Walter Flamenbaum, M.D.
Vice-chairman

John Baldoni, Ph.D.

Director

John Baldoni, Ph.D.
Director

Jennifer Buell, Ph.D.

Chief Executive Officer

Jennifer Buell, Ph.D.
Chief Executive Officer

Marc Van Dijk, Ph.D.

Chief Technology Officer

Marc Van Dijk, Ph.D.
Chief Technology Officer

Patrick Jordan, MBA

Vice President of Business Operations

Patrick Jordan, MBA
Vice President of Business Operations

Sonia De Munari, Ph.D., MBA

Head of Portfolio Strategy and Program Management

Sonia De Munari, Ph.D., MBA
Head of Portfolio Strategy and Program Management

Sandra Craig

Head of Manufacturing

Sandra Craig
Head of Manufacturing

Kimberly Ha

Head of Investor Relations

Kimberly Ha
Head of Investor Relations

Pipeline

MiNK's lead product candidate AGENT-797 is in multiple Phase 1 clinical trials with clinical and preclinical readouts anticipated later this year and in 2022. Our research team is focused on developing potential first-or best-in-class therapies using a next- generation technology platform to develop novel engineered iNKT cell therapies and bispecific iNKT cell engagers.

Product

Preclinical

Ph1

Ph2

Ph3

Native iNKT Cells
AGENT-797
Mechanism/Indication:
Solid Tumors
Anticipated Milestones:
H1-22: Phase 1 read-out
AGENT-797 + Checkpoint Antibodies
Mechanism/Indication:
Solid Tumors
including but not limited to NSCLC, HCC, SCCHN
Anticipated Milestones:
H1-22: Phase 1 read-out
AGENT-797
Mechanism/Indication:
r/r Multiple Myeloma
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Indication:
GvHD
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Indication:
ARDS Secondary to COVID-19
Anticipated Milestones:
IND Filing H1 ‘21
Engineered iNKT Cells
Mechanism/Indication:
BCMA-CAR-iNKT
Mechanism/Indication:
Stromal target-CAR-iNKT
Mechanism/Indication Product Preclinical Ph1 Ph2 Ph3 Anticipated Milestones
Native iNKT Cells
Solid TumorsAGENT-797
H1-22: Phase 1 read-out
Solid Tumors
including but not limited to NSCLC, HCC, SCCHN
AGENT-797 + Checkpoint Antibodies
H1-22: Phase 1 read-out
r/r Multiple MyelomaAGENT-797
Phase 1 Readout in Q4 ‘21
GvHDAGENT-797
Phase 1 Readout in Q4 ‘21
ARDS Secondary to COVID-19AGENT-797
IND Filing H1 ‘21
Engineered iNKT Cells
BCMA-CAR-iNKT
Stromal target-CAR-iNKT